Trendlines reveals MVP Stimatix valued at US$43 mil

SINGAPORE (Apr 9): The Trendlines Group has revealed that colostomy-device company Stimatix GI is its “Most Valuable Portfolio" company.

Trendlines, the Israeli investment and innovation commercialisation company, holds a 28.2% stake in Stimatix. As at its last valuation on Dec 31 2017, the stake is said to be worth US$42.6 million ($56 million).

Trendlines says B. Braun plans to market the product internationally from mid-2018. It is currently in the process of completing a high-volume manufacturing facility for the products to meet the product launch which is scheduled for mid-2018.

---

Related Stories

• Trendlines expects proceeds of $8 mil if sale of portfolio company is completed
• Trendlines urges investors to focus on long-term growth, not lumpy earnings
• The Trendlines Group – from seed to market

---